Evidence map›Paper›PMID 31332716›Full record

ArticleJournal of bioenergetics and biomembranes2019

Hyperthermia potentiates cisplatin cytotoxicity and negative effects on mitochondrial functions in OVCAR-3 cells.

Arturas Sukovas, Giedre Silkuniene, Sonata Trumbeckaite, Aldona Jasukaitiene, Laima Degutyte-Fomins, Vida Mildaziene, Antanas Gulbinas, Rasa Baniene, Zilvinas Dambrauskas, Saulius Paskauskas

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bioenergetics and biomembranes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Magnetic Hyperthermia via ZnPharmaceutics · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Arturas SukovasDepartment of Obstetrics and Gynaecology Lithuanian University of Health Sciences, Eiveniu str.2, LT-50009, Kaunas, Lithuania. arturas.sukovas@lsmuni.lt.ORCID 0000-0001-7007-3959
Giedre SilkunieneInstitute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu str. 4, LT-50009, Kaunas, Lithuania.
Sonata TrumbeckaiteNeuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str. 4, LT-50161, Kaunas, Lithuania.
Aldona JasukaitieneInstitute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu str. 4, LT-50009, Kaunas, Lithuania.
Laima Degutyte-FominsDepartment of Biochemistry, Faculty of Natural Sciences, Vytautas Magnus University, Vileikos str. 8, 44404, Kaunas, Lithuania.
Vida MildazieneDepartment of Biochemistry, Faculty of Natural Sciences, Vytautas Magnus University, Vileikos str. 8, 44404, Kaunas, Lithuania.
Antanas GulbinasInstitute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu str. 4, LT-50009, Kaunas, Lithuania.
Rasa BanieneNeuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str. 4, LT-50161, Kaunas, Lithuania.
Zilvinas DambrauskasInstitute for Digestive Research, Lithuanian University of Health Sciences, Eiveniu str. 4, LT-50009, Kaunas, Lithuania.
Saulius PaskauskasDepartment of Obstetrics and Gynaecology Lithuanian University of Health Sciences, Eiveniu str.2, LT-50009, Kaunas, Lithuania.
Lithuanian University of Health Sciences · LTVytautas Magnus University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to determine the effects of hyperthermia, cisplatin and their combination on mitochondrial functions such as glutamate dehydrogenase (GDH) activity and mitochondrial respiration rates, as well as survival of cultured ovarian adenocarcinoma OVCAR-3 cells. Cells treated for 1 h with hyperthermia (40 and 43 °C) or cisplatin (IC50) or a combination of both treatments were left for recovery at 37 °C temperature for 24 h or 48 h. The obtained results revealed that 43 °C hyperthermia potentiated effects of cisplatin treatment: combinatory treatment more strongly suppressed GDH activity and expression, mitochondrial functions, and decreased survival of OVCAR-3 cells in comparison to separate single treatments. We obtained evidence that in the OVCAR-3 cell line GDH was directly activated by hyperthermia (cisplatin eliminated this effect); however, this effect was followed by GDH inhibition after 48 h recovery. A combination of 43 °C hyperthermia with cisplatin induced stronger GDH inhibition in comparison to separate treatments, and negative effects exerted on GDH activity correlated with suppression of mitochondrial respiration with glutamate + malate. Cisplatin did not induce uncoupling of oxidative phosphorylation in OVCAR-3 cells but induced impairment of the outer mitochondrial membrane in combination with 43 °C hyperthermia. Hyperthermia (43 °C) potentiated cytotoxicity of cisplatin in an OVCAR-3 cell line.

Indexed as

AdenocarcinomaHyperthermia, InducedMitochondriaMitochondrial MembranesOvarian NeoplasmsCell LineCisplatinFemaleGlutamate DehydrogenaseHumansNeoplasm ProteinsOxidative PhosphorylationOxygen ConsumptionCisplatinGlutamate DehydrogenaseNeoplasm ProteinsCisplatinGlutamate dehydrogenaseHyperthermiaMitochondriaOvarian cancerOVCAR-3

Identifiers

PMID31332716
OpenAlexW2964325935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.